FDA Accepts Application for New Lymphoma Combination Therapy

The U.S. FDA has accepted Roche's supplemental Biologics License Application for a combination therapy involving Lunsumio and Polivy. This treatment targets adult patients with relapsed or refractory large B-cell lymphoma. The application is supported by Phase III study data indicating a significant reduction in disease progression or death risk.